Drugs / C.001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07594236 | Apr 2026 → Dec 2028 expected | Stargardt disease, age-related macular degeneration, diffuse secondary choroid atrophy, dystrophies primarily involving the retinal pigment epithelium | Cellio Therapeutics Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C.001 | “This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.” NCT07594236 ↗ |
| Route | Other | “C.001 administered once via subretinal injection” NCT07594236 ↗ |